News

Treatment with Trevi Therapeutics’ nalbuphine extended-release (ER) tablets significantly reduced daily coughing frequency in people with idiopathic pulmonary fibrosis (IPF) and chronic cough. That’s according to top-line data from the Phase 2b CORAL trial (NCT05964335), which is evaluating three doses of the experimental oral therapy against a…

Let-7, an established tumor suppressor microRNA that controls gene activity, plays a key role in lung tissue repair and the development of pulmonary fibrosis (PF), which is marked by scarring of the lungs, a study discovered. Mice lacking let-7 in lung cells spontaneously develop lung injury, demonstrating that the…

Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) after a year of treatment, according to final data from two Phase 3 clinical trials. FIBRONEER-IPF (NCT05321069) enrolled 1,177 IPF patients, while FIBRONEER-ILD…

A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is expected to enroll up to 120 people at about 50 sites in the U.S., U.K., Germany, Austria, and Poland.

GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — and expects to report initial results later this quarter, per a company press release. With…

A committee of the European Medicines Agency (EMA) is recommending orphan drug status — a designation that aims to speed therapy development in rare diseases — for tranilast, the active ingredient in NXP002, an inhaled formulation from Nuformix for treating idiopathic pulmonary fibrosis (IPF). A decision by the…

A cancer immunotherapy known as ipilimumab was able to reduce scar formation and promote tissue regeneration in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF). Treatment boosted the immune system’s ability to clear senescent cells, or those that no longer divide or grow but accumulate in…

The abnormal accumulation of immune plasma cells in the lungs — and their subsequent generation of damaging antibodies — may be a key driver of idiopathic pulmonary fibrosis (IPF), according to new research by scientists from Rutgers Health. The researchers found that antibody-producing plasma cells first accumulated in the…

Blocking Piezo2, a protein receptor that senses mechanical forces in tissues — ones such as stress, strain, and stiffness — may be a new way to slow the progression of idiopathic pulmonary fibrosis (IPF), according to a study by U.S. researchers. The scientists, who noted that this was the…

Basal stem cells taken from the upper part of a patient’s respiratory tract can be expanded in the lab and then transplanted back into their lungs to treat idiopathic pulmonary fibrosis (IPF), according to a recent study. “Our clinical observations herein show that [basal cells] infusion is able to…